논문KCI 등재
Challenges and innovations in primary sclerosing cholangitis clinical trials: Evaluating HK-660S and the path forward: Editorial on “Safety and efficacy of HK- 660S in patients with primary sclerosing cholangitis: A randomized double-blind phase 2a trial”
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
참고문헌 (8)
관련 논문AI추천
A novel clinical trial for primary sclerosing cholangitis from Asia: All regional endeavors should improve global management of primary sclerosing cholangitis: Editorial on “Safety and efficacy of HK-660S in patients with primary sclerosing cholangitis: A randomized double-blind phase 2a trial”Atsumasa Komori대한간학회 · Clinical and Molecular Hepatology2025 · 제31권 제2호Critical considerations in evaluating the therapeutic potential of HK-660S for primary sclerosing cholangi tis: Letter to the editor on “Safety and efficacy of HK 660S in patients with primary sclerosing cholangitis: a randomized double-blind phase 2a trial”Haifeng He, Qi Liang, Yizi He, Yongzhi Xie대한간학회 · Clinical and Molecular Hepatology2026 · 제32권 제1호Correspondence to editorial on “Safety and efficacy of HK-660S in patients with primary sclerosing cholangitis: A randomized double-blind phase 2a trial”Do Hyun Park, Woo Hyun Paik대한간학회 · Clinical and Molecular Hepatology2025 · 제31권 제2호Safety and efficacy of HK-660S in patients with primary sclerosing cholangitis: A randomized double-blind phase 2a trialCe Hwan Park, Do Hyun Park, Gunn Huh, Hee Jin Kim, Heon Se Jeong, Joo Kyung Park, Moon Jae Chung, Sang Hyub Lee, Woo Hyun Paik대한간학회 · Clinical and Molecular Hepatology2025 · 제31권 제1호The More, the Better? Predicting Prognosis in Primary Biliary CholangitisBo Hyun Kim거트앤리버 소화기연관학회협의회 · Gut and Liver2018 · 제12권 제6호Clinical and serological prognostic markers in primary biliary cholangitisWilhelmi Markus대한간학회 · Clinical and Molecular Hepatology2021 · 제27권 제2호
이 간행물의 다른 논문 (84건)
Epidemiology of metabolic dysfunction-associated steatotic liver diseaseLinda Henry, Markos Kalligeros, Zobair M. Younossipp. 32-50Role of noninvasive tests in the prognostication of metabolic dysfunction-associated steatotic liver diseaseJimmy Che-To Lai, Sherlot Juan Song, Terry Cheuk-Fung Yip, Vincent Wai-Sun Wong, Grace Lai-Hung Wong, Yichong Jiang, Yue Wangpp. 51-75Precision medicine and nucleotide-based therapeutics to treat steatotic liver diseaseAndrea Caddeo, Stefano Romeopp. 76-93Microbiome-centered therapies for the management of metabolic dysfunction-associated steatotic liver diseaseJasmohan S. Bajaj, Jeremy Burton, Antonio Gil-Gómez, Huma Saeed, Juan Pablo Arab, Luis Antonio Díaz, Manuel Romero-Gomez, Marco Arrese, Mohammad Qasim Khanpp. 94-111Alcohol-associated liver disease: Natural history, management and novel targeted therapiesHugo López-Pelayo, Edilmar Alvarado-Tapias, Ana Clemente-Sánchez, Ramón Bataller, Jordi Gratacós-Ginès, Elisa Posepp. 112-133